Skip to content

Efficiveness and mechanism of transcranial alternating current stimulation in the treatment of major depressive disorder: a randomized, double-blind, parallel-controlled study

Efficiveness and mechanism of transcranial alternating current stimulation in the treatment of major depressive disorder: a randomized, double-blind, parallel-controlled study

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300067443
Enrollment
Unknown
Registered
2023-01-09
Start date
2023-01-11
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Major Depressive Disorder

Interventions

Treatment Group:tACS was treated 20 times, combined with esitalopram oxalate 10mg-20mg daily for 4 weeks
Control Group:TACS pseudo-stimulation treatment for 20 times, combined with esitalopram oxalate 10mg-20mg daily for 4 weeks.

Sponsors

Beijing Anding Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 55 Years

Inclusion criteria

Inclusion criteria: 1) Meet the DSM-V diagnostic criteria for major depressive episodes (single episode or recurrence); 2) Outpatients aged 18-55 years old, male or female; 3)HAMD-17 score =17 points, and HAMD-17 item 1 (depressed mood) score =2 points; 4) Not receiving treatment of MECT/ECT, TMS, tDCS, etc. one month before enrollment; 5) Not receiving treatment of antidepressant for this episode; 6) Have understood all Study content and sign informed consent.

Exclusion criteria

Exclusion criteria: 1) Meet the DSM-IV diagnosis of other psychiatric disorders; 2) Impaired skin integrity at electrode placement site, allergic to electrode gel or adhesive; 3) With implanted electronic stimulator 4) HAMD-17 item 3 (suicide ) Score = 3; 5) Patients with previous suicidal behavior or existing strong suicidal ideation; 6) Those who participated in any other clinical trial within 1 month before baseline; 7) Previous manic or hypomanic episodes; 8 ) Patients with severe or unstable organic diseases; 9) Women who are pregnant and breastfeeding, patients who cannot take appropriate contraceptive measures during the trial; 10) Have seizures, epilepsy, hydrocephalus or central nervous system History of tumor, acute brain injury and infection; 11) Patients who are deemed inappropriate by the investigator; 12) Researchers who participated in this study or their immediate family members;

Design outcomes

Primary

MeasureTime frame
Reduction rate of HAMD-17 total score;

Secondary

MeasureTime frame
Each factor score of HAMD-17;CGI;GAD-7;QIDS-SR16;PSQI;Electroencephalogram;MRI;

Countries

China

Contacts

Public ContactGang Wang

Beijing Anding Hospital, Capital Medical University

gangwangdoc@vip.163.com01058303005

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026